tumsasedgars / iStockphoto.com

8 June 2018Americas

BIO 2018: Allergan-tribe deal just the start, says former USPTO director

“The Saint Regis Mohawk Tribe issue is not unique to just life sciences—we’re likely to see it across the board. There’s likely been other transfers that are not yet public information,” said Teresa Rea, vice-chair of Crowell & Moring’s IP group and former director of the US Patent and Trademark Office (USPTO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More on this story

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

More features

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?